Vernalis Plc Ord (VNLPF) 0.5600 $VNLPF Vernalis and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vernalis Plc Ord (VNLPF) 0.5600 $VNLPF

Vernalis and Asahi Kasei Pharma Achieve Milestone
Marketwire - Thu Mar 27, 2:01AM CDT
SOURCE: Vernalis PLC

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01
M2 - Mon Feb 24, 9:25AM CST


Vernalis Announces Successful Completion of Study
Marketwire - Mon Feb 24, 8:18AM CST
SOURCE: Vernalis PLC

Appointment of Nominated Adviser and Broker
M2 - Mon Feb 10, 4:28AM CST
LSE: VER

Treasury Issues Fresh Rules to Speed Up Public Projects
by Constant Munda - All Africa Global Media - Tue Feb 04, 4:38AM CST
NATIONAL Treasury Secretary Henry Rotich said yesterday that all ministries, departments and state agencies should start the procurement process for their projects before they are allocated funds.

Vernalis Announces Successful Pivotal Single Dose Bioavailability Study with First Cough Cold Product, CCP-01
M2 - Mon Nov 25, 5:36AM CST
LSE: VER

Vernalis Announces Successful Study With CCP-01
Marketwire - Mon Nov 25, 1:10AM CST
SOURCE: Vernalis PLC

Other Central Nervous System Disorders - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pwfcw/other_central) has announced the addition of the "Other Central Nervous System Disorders - Pipeline Review, H2 2013" report to their offering. 'Other Central Nervous System Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Other Central Nervous System Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Central Nervous System Disorders. Scope - A snapshot of the global therapeutic scenario for Other Central Nervous System Disorders. - A review of the Other Central Nervous System Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Other Central Nervous System Disorders pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Other Central Nervous System Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Other Central Nervous System Disorders pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Other Central Nervous System Disorders Overview Therapeutics Development Companies Involved in Other Central Nervous System Disorders Therapeutics Development Drug Profiles - progesterone - Neuroprotection And Neural Regeneration Program - HF-1220 - mecasermin - rifampin - Oligonucleotide For Rett Syndrome - Protein Fractions Featured News & Press Releases Appendix Companies Mentioned - M et P Pharma AG - Newron Pharmaceuticals S.p.A. - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Vernalis plc For more information visit http://www.researchandmarkets.com/research/4p...er_central

Interim results for the six months ended 30 June 2013
M2 - Mon Jul 29, 4:31AM CDT
LSE: VER

Vernalis plc: Interim results for six months ended 30 June 2013
Marketwire - Mon Jul 29, 1:05AM CDT
SOURCE: Vernalis PLC

Nasopharyngitis (Common Cold) - Latest Pipeline Review Report
M2 - Wed Jul 17, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmqdtg/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2013" report to their offering. 'Nasopharyngitis (Common Cold) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngitis (Common Cold), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold). Scope - A snapshot of the global therapeutic scenario for Nasopharyngitis (Common Cold). - A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stag

Vernalis Initiates Phase Ib/II Proof-of-Concept Study with V81444
M2 - Fri Jul 12, 4:37AM CDT
Vernalis plc today announces that it has dosed the first subjects in a Phase Ib/II proof-of-concept (PoC) study of V81444, an A 2A antagonist which has potential applications for the treatment of Parkinson's disease and other disorders of the central nervous system (CNS).

Vernalis Initiates Phase Ib/II POC Study of V81444
Marketwire - Fri Jul 12, 1:08AM CDT
SOURCE: Vernalis PLC

Notice of Results for the Six Months Ended 30 June 2013
M2 - Thu Jul 11, 5:06AM CDT
LSE: VER

Announcement of Results for the year ended 31 December 2012
M2 - Wed Apr 10, 4:57AM CDT
Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2012.

Vernalis plc: Announcement of Results for year ended 31/12/12
Marketwire - Wed Apr 10, 1:09AM CDT
SOURCE: Vernalis PLC

Notice of Results for the Twelve Months Ended 31 December 2012
M2 - Thu Mar 21, 7:39AM CDT
Vernalis plc today announces its year end results for the twelve months ended 31 December 2012 will be released on Wednesday, 10 April 2013. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com .

First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
PR Newswire - Mon Mar 11, 8:00AM CDT
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01.

First product in cough cold pipeline achieves proof-of-concept
M2 - Wed Mar 06, 7:09AM CST
LSE: VER

Vernalis and Servier Extend Oncology Collaboration
M2 - Wed Mar 06, 7:08AM CST
LSE: VER
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 0

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

Síminn hf. Achieves Strong Growth in Q2 2025 Results

Updated Category News Views 303

Exciting Financial Highlights from Síminn hf. for Q2 2025 In the second quarter of 2025, Síminn hf. reported remarkable financial growth, demonstrating their resilient operations and commitment to enhancing customer value. The total revenue surged to ISK 7,196 million, marking a 4.7% increase compared to Q2 2024, where revenues stood at ISK 6,871 million. This positive...

Continue Reading
Pacesetter Joins Inc.'s 2026 Best Workplaces List

Updated Category News Views 33

Pacesetter Technology Earns a Spot on Inc.'s Renowned List How many times have we heard companies rattle on about employee satisfaction and culture? But this time, we're talking about a company, Pacesetter Technology, that didn't just talk the talk—they walked right into Inc.'s 2026 Best Workplaces spotlight. And in an era where employers hold all the cards, that's no...

Continue Reading
Discover Meiyume's Innovative Beauty Solutions at Cosmopack

Updated Category News Views 272

Unveiling Meiyume at Cosmopack Asia 2025 Hong Kong, leading the way in beauty solutions, is set to host an influential event as Meiyume showcases its innovative initiative titled SEEDED — Rooted in Intelligence, Connected Through the Beauty Vein at Cosmopack Asia. With a strong foothold in packaging and product development, Meiyume leverages its proprietary Beauty...

Continue Reading
MAHA Action, Inc. Announces Support for Zach Lahn's Governor Bid

Updated Category News Views 215

MAHA Action, Inc. Endorses Zach Lahn for Iowa Governor MAHA™ Action, Inc., a prominent advocate for health freedom, proudly announces its endorsement of Zach Lahn as the next Governor of Iowa. Lahn has launched an Iowa First platform aimed at empowering residents and improving personal liberties. Commitment to Health Freedom Lahn has emerged as a vigorous champion of...

Continue Reading
Couchbase Reports Impressive Q1 Earnings Amid Rising Demand

Updated Category News Views 309

Financial Performance Highlights for Couchbase Couchbase, Inc. (NASDAQ: BASE), the leading developer data platform that powers critical applications in today’s AI-driven world, has unveiled its financial performance for the first quarter ended April 30, 2025. With a remarkable increase in revenue and strong annual recurring revenue (ARR), Couchbase has demonstrated the...

Continue Reading